Docoh
Loading...

BCTX BriaCell Therapeutics

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

BCTX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

17 Oct 21
31 Jul 22

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

29.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 16 15 +6.7%
Opened positions 8 15 -46.7%
Closed positions 7 0 NEW
Increased positions 0 0
Reduced positions 3 0 NEW
13F shares
Current Prev Q Change
Total value 8.88M 1.45M +513.5%
Total shares 4.54M 3.22M +41.3%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
L1 Capital Global Opportunities Master Fund 1M $0 0.0%
L5 Capital 725K $3.67M NEW
CVI Investments 600K $3.63M NEW
Lind Global Macro Fund 562.6K $0 0.0%
Empery Asset Management 500K $0 0.0%
Armistice Capital 375K $675K NEW
Bigger Capital Fund L P 277.5K $0 0.0%
Altium Capital Management 209.54K $377K -58.1%
Murchinson 100K $180K NEW
Redmond Asset Management 75K $135K -43.1%
Largest transactions
Shares Bought/sold Change
L5 Capital 725K +725K NEW
CVI Investments 600K +600K NEW
Armistice Capital 375K +375K NEW
Altium Capital Management 209.54K -290.46K -58.1%
Sabby Management 0 -160.18K EXIT
Murchinson 100K +100K NEW
Redmond Asset Management 75K -56.73K -43.1%
Warberg Asset Management 32K +32K NEW
Eqis Capital Management 0 -16.34K EXIT
MS Morgan Stanley 10.75K +10.75K NEW

Financial reports

No filings

Proxies

No filings